Future studies should integrate gene editing technologies with BC organoids to explore additional driver genes and therapeutic targets, which could facilitate early diagnosis and timely intervention.Truong et al. used Luminal BC PDOs to reveal that PELP1/SRC-3 and PFKFB kinase collaboratively drive tumor stem cell proliferation and therapeutic drug resistance. This evidence concerns the gene NCOA3 and breast cancer.